Kornimate/medical-research-clean huggingface dataset:
effects of myofascial release therapy and endurance training on mechanical back pain

Conditions: Back Pain, Low

Summary: this study is a randomized clinical trial to determine the effects of myofascial release therapy versus endurance training of trunk extensor muscles on pain, disability and muscle endurance in patients with mechanical back pain. a sample of 24 patients will be taken and divided into two groups each with 12 patients. group a will receive myofascial release therapy and conventional physical therapy while group b will endurance training of trunk extensors and the conventional physical therapy protocol. the conventional physical therapy protocol will include a hot pack, back care advice, and postural modifications. the session will be around 40 to 45 min for each patient with four sessions per week. a total of four-week treatment regime will be given to the patients and assessment of the patient's pain, disability, and endurance with nprs (numeric pain rating scale), rolland morris disability questionnaire and sorenson test will be done at the baseline, after the completion of treatment at pre interventional and post interventional to observe the long-term effects. the data will be analyzed using spss.

mechanical low back pain is an injury of an anatomic structure in the low back. it accounts for 97% of cases arising from spinal structures such as bone ligaments, nerves, etc. in chronic low back pain, exercise therapy has become a first-line treatment and should be routinely used. fascia is a form of connective tissue made up of collagen, surrounds the body parts, and resists tissue tensile load. fascial injury and adhesions are common and can lead to pain, restricted motion, and swelling. the treatment of the fascial injury is necessary to relieve those symptoms. there are many treatments for mechanical back pain and this study focuses on two new treatment techniques for mechanical back pain. the first is the myofascial release therapy, a manual approach that focuses on the structural segmentation of fascia and involves the application of gentle pressure while stretching the body's connective tissues. the other treatment technique is the endurance training of the trunk extensor muscles that involve the treatment which is directed to endurance training of erector spinae and latissimus dorsi. the current study is novel in a way that there is limited literature about myofascial release therapy versus endurance training of trunk extensor muscles in patients with mechanical back pain. both methods were employed to see if they improve pain along with accompanying disability and muscle endurance.

Eligibility criteria:
inclusion criteria: * history of mechanical low back pain * back pain without association with leg pain exclusion criteria: * any bony, soft tissue or systemic disease * pregnant females * radiculopathy * patient with spinal deformities and fractures

Keywords: mechanical low back pain myofascial release endurance training nprs
endomaxx endoluminal valve technology (evt) compared to endomaxx

Conditions: Malignant Esophageal Strictures

Summary: this is a prospective, single blinded, randomized study of endomaxx endoluminal valve technology (evt) fully covered esophageal stent with valve for the treatment of malignant strictures of the lower esophagus. the purpose of this study is to evaluate improvement of dysphagia due to esophageal stricture with endomaxx endoluminal valve technology (evt) fully covered esophageal stent with valve (investigational device) compared to the endomaxx fully covered esophageal stent (reference device).


Eligibility criteria:
inclusion criteria: 1. patient is 18 years of age or older 2. patient (or legal representative) is able to understand and provide signed informed consent 3. patient has a malignant stricture of the distal esophagus or gastric cardia requiring stent placement across the gastroesophageal junction. exclusion criteria: 1. patient is unwilling or unable to comply with the follow-up schedule 2. patient is contraindicated for endoscopic procedure for any reason 3. patient presents with esophagorespiratory fistula 4. patient has previously undergone esophageal stenting or esophagectomy 5. female patient is pregnant, breastfeeding, or premenopausal and not using an effective method of contraception 6. patient's esophageal tumor length exceeds that which can be treated with a single stent (maximum lesion length 9.5cm) 7. removal of stent is scheduled to occur within six months 8. patient has trouble swallowing or experiences regurgitation for reasons which are not related to his/her esophageal cancer 9. any other factor identified by the investigator that would disqualify the prospective patient from participation in the study including but not limited to coagulative disorders and anesthetic risk.

Keywords: esophageal cancer dysphagia regurgitation
the role of progesterone and pif for successful implantation and on-going pregnancy in assisted reproductive technology

Conditions: Infertility

Summary: the aim of this study is to achieve a more profound understanding of the endocrine alteration in luteal progesterone level after gonadotrophin stimulated ivf/icsi cycles and to explore the optimal progesterone level needed for securing implantation and development of early pregnancy. the second part of the project will determine the value of preimplantation factor (pif) measurement in embryo culture medium as a possible tool for improved embryo selection and the use of pif as an early pregnancy serum marker for healthy implantation and embryo development. ivf: in vitro fertilisation, icsi: intracytoplasmic sperm injection.


Eligibility criteria:
inclusion criteria: -all women undergoing ivf/icsi treatment at the participating clinics in either antagonist protocol or long agonist protocol will be offered participation. exclusion criteria: -prior participation in the study

Keywords: infertility ivf/icsi progesterone preimplantation factor (pif)
ethyl eicosapentanoic acid (ethyl-epa) for treating major depression

Conditions: Depressive Disorder; Depression

Summary: the purpose of this study is to examine the effectiveness of ethyl-eicosapentanoic acid (ethyl-epa), an omega-3 fatty acid, in treating depression.

evidence suggests that omega-3 fatty acids may help reduce symptoms of depression. this study will determine whether ethyl-epa, an omega-3 fatty acid, can be used safely and effectively to treat major depression. participants will be randomly assigned to receive either ethyl epa-containing pills or placebo daily for 8 weeks. each week, participants will be asked to complete questionnaires which will be used to assess the severity of their depression.

Eligibility criteria:
inclusion criteria: * major depressive disorder exclusion criteria: * serious comorbid psychiatric disorder * unstable medical illness * prior use of any omega-3 fatty acid product

Keywords: fatty acids, omega-3 antidepressive agents eicosapentanoic acid
double blind placebo control opipramol-baclofen treatment for addiction

Conditions: Drug Abuse

Summary: the aim of this study is examining the combination of two fda approved drugs, opipramol and baclofen, which may increase rehabilitation from psychoactive substances. previous studies have indicated a connection of sigma-1 receptor to cocaine abuse and raised the possibility that these receptors as mediators of drug craving . however previous studies showed partial efficacy with no significant relapse in relapse rates. the same is true for the use of gabab-1 receptor antagonist. opipramol is a selective agonist for sigma-1 receptor. it is clinically used as an antidepressant and anxiolytic agent. moreover, previous open and controlled trials indicated that the gabab-1 antagonist baclofen partial efficacy in suppressing withdrawal symptoms in alcohol addicts and cocaine. our studies in an animal model for addiction have shown a significant effect of the combine treatment of the indicated medications both in decreasing relapse and increase of -number of respondents.


Eligibility criteria:
inclusion criteria: * age will be 60-18, both sexes, seeking treatment in order to stop the consumption of materials exclusion criteria: * did not include trial addicts with co-morbidity, kidney, heart, metabolic, neurological and psychiatric disorders (psychosis, chronic depression).
strategies to prevent pneumonia (stop pneumonia)

Conditions: Ventilator Associated Pneumonia

Summary: this study tests whether special oral care provided by nurses to critically ill patients who are on a breathing machine (mechanical ventilator) can help to reduce the build-up of dental plaque on the teeth and reduce the risk of pneumonia.

pneumonia is the leading cause of death from hospital-acquired infections. intubation and mechanical ventilation greatly increase the risk of bacterial ventilator associated pneumonia. growth of potentially pathogenic bacteria in dental plaque of critically ill patients provides a nidus of infection for microorganisms that have been shown to be responsible for the development of ventilator associated pneumonia. since these organisms are concentrated in dental plaque, removal of organisms from the oral cavity by oral care interventions is a theoretically attractive method to reduce the risk of development of ventilator associated pneumonia. however, evidence-based protocols for oral care of mechanically ventilated patients are not available. results of the study have the potential to improve nursing care, and to positively affect patient well-being, morbidity, mortality, and health care costs.

Eligibility criteria:
inclusion criteria: * 18 years or older, admitted to one of four intensive care units at the study hospital, breathing tube in place, and on a breathing machine (mechanical ventilator) exclusion criteria: * breathing tube in place for more than 24 hours prior to entry into the study, absence of teeth, or a medical diagnosis of pneumonia when the breathing tube is put in.

Keywords: pneumonia dental health critical care
covid-19 and hereditary metabolic diseases

Conditions: Covid19; Metabolism, Inborn Errors

Summary: no additional risk factors have been identified in patients with inherited metabolic diseases (imd) for contracting or presenting complications of covid-19 compared to the general population. yet, imd patients have cell/tissue alterations that could constitute a potential direct or indirect target for the virus. we do not know the impact of this infection on patients suffering from mhm, nor the possible effect of specific treatment of mhm on the evolution of covid-19. this study will collect french imd patients having or having had covid-19 infection. the main objective is to estimate among imd patients contracting covid-19 the frequency of disease aggravation or metabolic decompensation. the secondary objectives will be : a. to evaluate the incidence of covid-19 diagnosed in a given group of imd when the number of patients with this imd is known (urea cycle deficiency, gaucher disease). b. to evaluate the impact of imd on the and severity of covid-19 infection


Eligibility criteria:
inclusion criteria: * child or adult patient with a diagnosis of imd * symptomatic or asymptomatic patient tested positive for covid-19 (pcr and/or serology) * symptomatic patient non tested but with strong clinical suspicion for covid-19 * patient affiliated with the health insurance exclusion criteria: * inability to receive informed information * persons deprived of liberty

Keywords: covid-19 inherited metabolic diseases
survival outcome after minilaparotomy for the treatment of colorectal cancer

Conditions: Colorectal Cancer

Summary: the primary aim of this study is - to determine the difference of survival outcome (3-year overall survival, 3y os) between after minilaparotomy and after laparoscopy.. other aims include to determine the data below when minilaparotomy and laparoscopy are compared with each other. * 3-year disease free survival, 3y dfs * 5-year overall survival, 5y os * 5-year disease free survival, 5y dfs * local recurrence rate, lrr * postoperative complications incidence and mortality at 30 days


Eligibility criteria:
inclusion criteria: * colorectal cancer with pathological results. * colorectal cancer preliminary diagnosed during colonoscopy. * no confirmed metastasis. * no comorbidity of other malignancy. * the primary tumor is less than 10 cm. * no organ dysfunction. * the patient and his families totally agree with the whole investigative procedure, and sign the written informed consent form. exclusion criteria: * diagnosed with any other malignancy within 5 years. * comorbidity of emergent conditions like perforation. * former colorectal surgery history which may affects digestive tract reconstruction. * need combined organ resection. * asa grade iv or v. * pregnant or lactating women. * severe mental diseases. * severe cardiopulmonary diseases which reduce operation tolerance. * systematic steroid therapy lasting for more than 1 month. * intolerant of laparoscopy. * no written informed consent form signed.

Keywords: colorectal cancer minilaparotomy survival
sws and daytime functioning in chronic fatigue syndrome (saffe)

Conditions: Chronic Fatigue Syndrome

Summary: the investigators wish to investigate whether enhancement of sws, which is seen after a drug called sodium oxybate, reduces the impact of sleep disruption in cfs on daytime function, specifically sleepiness and mental performance. this is a safe and well-tolerated drug that is licensed for excessive daytime sleepiness (eds) and cataplexy associated with narcolepsy. the investigators will study 12 patients diagnosed with cfs using international diagnostic guidelines. the investigators will record overnight sleep with eeg (brainwave) measurement on the 1st and 4th nights of a 4 night period during which sodium oxybate and placebo will be taken nightly, and the investigators will measure next-day sleepiness, mental performance and fatigue, and compare drug and placebo nights.

chronic fatigue syndrome (cfs), characterised by chronic disabling fatigue, sleep impairment and other symptoms, is associated with neither a currently identifiable disease process nor major psychiatric illness, and has an estimated prevalence in primary care of 1-2%. sleep impairment is common in nearly everyone with cfs, with both daytime sleepiness and unrefreshing nighttime sleep reported, and consequent impact on daytime function. it may be that fundamental regulatory processes that control sleep are disturbed in cfs, leading to different effects on sleep and daytime symptoms depending on the subject's prior sleep, daytime routine, medication and other factors. the investigators contacts with patient groups have indicated that patients are generally confident that on days when their sleep is better they perform better in the day. there is growing evidence that deep, slow wave sleep (sws) is altered in cfs, and this may suggest impairment of build up of sleep pressure during the day.

Eligibility criteria:
inclusion criteria * meeting criteria for cfs according to both the revised cdc (fukuda 5) and canadian diagnostic systems. * aged 25-65. * good grasp of the english language. exclusion criteria * taking any of the following medication: opioids, tramadol, phenytoin, valproate, ethosuximide, benzodiazepines, zolpidem, zopiclone, zaleplon, antidepressant except \<30mg amitriptyline, or any other medications likely to interact with sodium oxybate or with sleep in the opinion of the investigators. * current major psychiatric disorder. * unusual sleep schedule; (bedtime routines that fall outside 9 p.m. to 10 a.m.; usual time in bed \> 12 hours). * pregnancy, lactation or being female and not using reliable contraception. * relevant abnormal clinical findings at screening visit. * taken alcohol in the 24 hours before each study visit or drugs of abuse in the week before each study visit

Keywords: chronic fatigue syndrome
a study to evaluate the safety of thr-149 in subjects with diabetic macular edema (dme)

Conditions: Diabetes Mellitus; Diabetic Retinopathy; Diabetic Macular Edema

Summary: this study is conducted to evaluate the safety of a single intravitreal injection of thr-149.


Eligibility criteria:
inclusion criteria: * male or female aged 18 years or older * type 1 or type 2 diabetes mellitus * central-involved dme with central subfield thickness of ≥ 320µm on spectralis® spectral domain optical coherence tomography (sd-oct) or ≥ 305µm on non-spectralis sd-oct, in the study eye * best-corrected visual acuity (bcva) ≤ 62 and ≥ 23 etdrs letter score in the study eye * written informed consent obtained from the subject prior to screening procedures exclusion criteria: * macular edema due to causes other than dme * concurrent disease in the study eye, other than central-involved dme, that could compromise bcva, require medical or surgical intervention during the study period or could confound interpretation of the results * any condition that could confound the ability to detect a change in central subfield thickness in the study eye * previous confounding treatments / procedures, or their planned / expected use during the study period * presence of neovascularization at the disc (nvd) in the study eye * uncontrolled glaucoma in the study eye * any active ocular / intra-ocular infection or inflammation in either eye * poorly controlled diabetes mellitus * uncontrolled hypertension
evaluation of long-term quality of life in children supported with extracorporeal membrane oxygenation (ecmo)

Conditions: Extracorporeal Membrane Oxygenation Complication; Critical Care

Summary: the main objective of this prospective transversal comparative study is to describe the quality of life of children supported by ecmo. these patients are described in detail at the nantes university hospital, in particular the elements of neurological monitoring. these results will be analyzed in reference to a population hospitalized at the same age, in the same period, and sharing the same diagnostic categories.


Eligibility criteria:
inclusion criteria: * patients accepted in pediatric intensive care at the nantes university hospital between january 2014 and december 2022 * patients less than 10 years old at admission to the intensive care unit, * patients older than 2 years at the time of the cross-sectional evaluation * for the ecmo group: patients supported by ecmo * for the control group: patient intubated-ventilated for more than 48 hours and/or having received amines and/or having received organ support other than ecmo. * patient affiliated to the social security. * patient with parents who do not object to the study exclusion criteria: * known genetic pathology or malformative association at the time of admission to the intensive care unit that could lead to severe neurodevelopmental deficits, independently of the medical events that resulted in the admission to the intensive care unit * language difficulty that does not allow for complete information and questionnaire collection

Keywords: pediatric intensive care quality of life
comparison of the torsional handpiece to conventional handpiece during routine phacoemulsification

Conditions: Cataract Extraction

Summary: the purpose of this study is to evaluate the visual outcomes, amount of inflammation, endothelial cell loss, and the efficiency of a torsional handpiece compared to a conventional handpiece during surgery to remove your cataracts.

with the introduction of new phaco-emulsification systems, the cataract surgery has become a very safe procedure. the new machines combine fewer surges, lower amount of ultrasound and more controlled anterior chamber depth, as well as lower incidence of thermal burns of the incision site.1-4 alcon's infiniti vision system phacoemulsification machine includes now a torsional handpiece (ozil™). the goal of ozil™ is to minimize the surgery impact by reducing temperature increase, turbulence and incision stress. this handpiece has a sideways movement that does not repel the cataract during its extraction making the removal more continuous, maintains occlusion which facilitates vacuum build-up and reduces flow through the anterior chamber decreasing turbulence, therefore reducing the likelihood of lens particles damaging the corneal endothelial cells. the purpose of this study is to compare visual outcomes, induction of inflammation, endothelial cell loss and efficiency of the torsional handpiece vs. the conventional phacoemulsification handpiece when using the alcon infiniti vision system.

Eligibility criteria:
inclusion criteria: * bilateral senile cataracts. * cataract density up to 3+. * 50 years of age or older. * patient must desire cataract extraction. * expected maximum of 4 weeks and minimum of 1 week interval between first and second eye surgeries. * willing and able to comply with scheduled visits and other study procedures. exclusion criteria: * preoperative ocular pathology: amblyopia, rubella cataract, proliferative diabetic retinopathy, macular edema, retinal detachment, uveitis, history of iritis, iris neovascularization, medically uncontrolled glaucoma, microphthalmus or macrophthalmus, optic nerve atrophy, macular degeneration with visual acuity of less than 20/40, glaucoma with the presence of visual field defects * corneal irregularities potentially affecting visual acuity: keratoconus, corneal dystrophy, corneal opacities. * low endothelial cell count (less than 1500 cells/mm2) * any concurrent infectious/non infectious conjunctivitis, keratitis or uveitis in either eye. * any clinically significant, serious or severe medical or psychiatric condition. * participation in (or current participation) any investigational drug or device trial within the previous 30 days prior to the start date of this trial. * previous intraocular or corneal surgery. * other ocular surgery at the time of the cataract extraction.

Keywords: cataract
visual function with contralateral acrysof® restor® aspheric sn6ad1 and sn6ad3

Conditions: Cataract

Summary: the objective of this study is to prospectively evaluate the visual parameters in a series of patients after phacoemulsification cataract surgery in a series of patients bilaterally implanted with the acrysof® restor® aspheric intraocular lens (iol) models sn6ad1 and sn6ad3.


Eligibility criteria:
inclusion criteria: * prospective subjects should be 21 years of age and older, be of any race and gender and meet study entry criteria. subject must require extraction of cataracts followed by implantation of a posterior chamber intraocular lens (iol). subjects must be candidates for bilateral removal of the natural crystalline lens followed by implantation of a multifocal iol and be willing and able to complete all follow-up visits. exclusion criteria: * subjects with pre-existing conditions that could skew the results or are contraindications for the acrysof® restor® iol should be excluded from the study. please consult the acrysof® restor® aspheric product inserts under "precautions" for subject groups that should be excluded from this study. * all subjects must have ≤ 0.75 diopters of astigmatism preoperatively as measured by keratometry (k) readings. if the surgeon determines that a correction of cylinder is necessary postoperatively, this may be performed after the three month evaluations are completed.

Keywords: cataract iol restor aspheric bilateral cataract